Saturday, 29 April 2017

Global med-tech firms, India locked in tussle after stent price sting

Grab Free Stock Tips click here >>

A group of global medical technology companies plans to tell Indian officials next month that any further price control measures would risk future investments and make them less likely to introduce new products in the country, according to an industry source familiar with the matter. The lobbying effort by Abbott Laboratories, Boston Scientific, Johnson & Johnson, and others comes after the government of Prime Minister Narendra Modi in February set a price cap for stents - small wire-mesh structures used to treat blocked arteries - slashing prices that patients pay for some devices by about 75 percent.

No comments:

Post a Comment